Blocking PD-L1 pathway: Changing landscape in urothelial cancer

Speaker: Andrea Necchi

A. Necchi provides an expert overview across data from atezolizumab, durvalumab and nivolumab studies in urothelial cancer as presented at ASCO 2016 Annual Meeting. It is an exciting time in this field; after decades of therapeutic silence these agents provide 25-30% response rate in the overall population in relapsed setting and 8 month overall survival with observed increase in patients with PD-L1-positive tumours. The problem will be to identify patients who may benefit from the treatment.

Discussion Points

  • Overview of results from the studies presented at ASCO 2016 Annual Meeting: 
    • Abstract  4515: Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).
    • Abstract  4501: Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.
    • Abstract  4502: Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
  • Critical issues in checkpoint inhibition in patients with relapsed urothelial cancers
  • Future perspective in the management of urothelial cancer